Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review

Immune checkpoint inhibitors are the most important new medications in oncology and include inhibitors of programmed cell death protein-1 (PD-1) such as Pembrolizumab, Nivolumab, and Cemiplimab. These anticancer agents prevent tumour immune evasion and have been associated with a range of immune-rel...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncological medicine 2020-08, Vol.2020 (2020), p.1-5
Main Authors: Chew, R., Hartnett, G., Eriksson, L., Chern, B., Bigby, K., Seidl, B., Vickers, M. L., Gericke, C.
Format: Article
Language:English
Subjects:
Apoptosis
Ataxia
Cancer therapies
Case Report
Case reports
Fecal incontinence
Immunoglobulins
Immunotherapy
Literature reviews
Lung cancer
Lymphoma
Magnetic resonance imaging
Melanoma
Metastasis
Monoclonal antibodies
Proteins
Systematic review
T cells
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors are the most important new medications in oncology and include inhibitors of programmed cell death protein-1 (PD-1) such as Pembrolizumab, Nivolumab, and Cemiplimab. These anticancer agents prevent tumour immune evasion and have been associated with a range of immune-related adverse events (irAEs) including those involving the nervous system. In this case report and literature review, we present the first case of inflammatory myeloradiculitis secondary to Pembrolizumab. We also summarise the characteristics, treatment, and outcomes of other cases reported in the literature which include a component of myelitis. Finally, we make general recommendations on management.
ISSN:2090-6706
2090-6714
DOI:10.1155/2020/8819296